《老年弥漫大B细胞淋巴瘤诊断与治疗专家共识(2024年版)》解读

Interpretation of expert consensus on the diagnosis and management of elderly patients with diffuse large B-cell lymphoma(2024)

随着我国人口老龄化来临,老年弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)患者的比例上升。老年患者对化疗耐受性差,治疗方案需要个体化制定。为提高我国临床医师对老年DLBCL的诊断及治疗水平,中华医学会血液病学分会淋巴细胞疾病学组和中国临床肿瘤学会(CSCO)抗淋巴瘤联盟组织相关专家制定了《老年弥漫大B细胞淋巴瘤诊断与治疗专家共识(2024年版)》。为更好地指导临床实践,本文对该共识的重点内容进行解读。

With the aging of the general population in China,the number of elderly patients with diffuse large B-cell lymphoma(DLBCL)will continuously increase,which requires special considerations.Individualized treatment is required to maximize therapeutic potential while minimizing the risk of toxicity.In order to improve the diagnosis and treatment of DLBCL in the elderly in China,the Lymphocyte Disease Group of the Hematology Division of the Chinese Medical Association and the Anti-Lymphoma Alliance of the Chinese Society of Clinical Oncology(CSCO)have organized relevant experts to formulate the"expert consensus on the diagnosis and management of elderly patients with diffuse large B-cell lymphoma(2024)".To better guide clinical practice,this paper intends to interpret assessment of host factors and individualized stratified treatment of this consensus.